Pronota Signs Agreement with Molecuence to Develop Protein Biomarkers for Stroke

Pronota will use its proprietary biomarker discovery platform MASStermind and verification platform MASSterclass on the project.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.